21 45 4

MGAH22 (margetuximab): HER2+ Tumors

Phase 2 clinical study in patients with HER2 positive solid tumors.
Learn more: MGAH22
Learn more: ClinicalTrials.gov

Platform Fact Sheets

 DART
 Cancer Stem-like Cells
 Fc Optimization

Media Kit / Downloads

Fact Sheets

Fc Optimization Platform (.PDF, 231.26 Kb)

Dual-Affinity Re-Targeting (DART) Platform Overview (.PDF, 1.03 Mb)

Cancer Stem Cell Platform Overview, (.PDF, 2.03 Mb)

Corporate Fact Sheet, (.PDF, 1.39 Mb)

Corporate Logo

MacroGenics Logo (vector) (.EPS, 996.84 Kb)

MacroGenics Logo (bitmap), (.JPG, 135.84 Kb)